
Medicaid Patients' Access to Opioid Treatment Medications Surged Nationwide, RTI Study Finds
New JAMA Network Open study shows MOUD access among Medicaid beneficiaries rose from 60% to 69% between 2019-2023, with 45 states seeing increases.
Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.

New JAMA Network Open study shows MOUD access among Medicaid beneficiaries rose from 60% to 69% between 2019-2023, with 45 states seeing increases.

In a region flooded with 17 million prescription opioids, proposed Medicaid work requirements and funding cuts threaten to dismantle the safety net that has helped hundreds achieve recovery from addiction.

Albertsons and Safeway parent company agrees to $773 million national settlement, with Oregon receiving up to $38.2 million over nine years to expand addiction and recovery services.

UC San Diego and SDSU study of 2.8 million students finds local flavor bans reduce e-cigarette use by 20% with no increase in cigarette smoking, challenging industry arguments.

New research reveals 20% of US pharmacies block access to buprenorphine, with independent pharmacies and southern states showing significantly higher refusal rates for this life-saving opioid addiction medication.

Wake Forest research reveals e-cigarette taxes reduced vaping among heterosexual teens by 3-4 percentage points, yet had no effect on LGBQ youth who use nicotine to cope with bullying and emotional distress.

JAMA research letter reveals 24.3% decline in long-term opioid therapy from 2015-2023, even as co-prescribing with gabapentinoids rises sharply, raising new safety concerns for chronic pain patients.

New ASAM Criteria volume establishes dedicated clinical standards for youth SUD treatment, emphasizing brain development, family engagement, and integrated mental health care

BMJ study of 2.5 million Medicaid births finds children exposed to buprenorphine in utero have no greater risk of ADHD, autism, or other neurodevelopmental disorders compared to methadone exposure.